GL1X · GenesisL1 explorer

Research workbench

Mao inhibition by rasagiline analogues

Analyse Mao inhibition by rasagiline analogues in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
2C67
Type
protein
Length
993 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Amine oxidase (flavin-containing) B
EC
1.4.3.4
UniProt
P27338
Ligands
FAD, RM1
Pockets
17 · best druggability 0.86

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 21% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAmine oxidase (flavin-containing) B (EC 1.4.3.4)protein49939% helix, 20% strandP27338
BAmine oxidase (flavin-containing) B (EC 1.4.3.4)protein49438% helix, 21% strandP27338

Ligands and binding sites

  • FAD · Flavin-adenine dinucleotide · ligand · 2 copies · chains A, B
  • RM1 · N-methyl-1(R)-aminoindan · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

17 pockets found on a 1 Å grid, 9 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13450.860.9654FAD, RM1
23500.860.9657FAD, RM1
3550.670.9517empty
4520.670.9518empty
5500.600.9223empty

Interfaces

1 interface between chains.

  • A–B · 2121 Ų buried · 37 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 cofactor (flavinylation).

Compared structures

  • 2C67 · MAO inhibition by rasagiline analogues · the same entry in another collection · chain A against A, TM-score 1.00
  • P27338 · AlphaFold monomer V2.0 prediction for amine oxidase [flavin- containing] B (P27338) · a predicted model of the same protein · chain B against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.